Lineage Cell Therapeutics Inc. has announced a change in its independent registered public accounting firm following the merger of its current auditor, Moss Adams LLP, with Baker Tilly US, LLP. Effective June 3, 2025, Moss Adams resigned as the company's auditor, and the Audit Committee of Lineage Cell Therapeutics' Board of Directors has appointed Baker Tilly as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. This transition comes after Moss Adams had been the appointed auditor since June 2024. The company confirmed that there were no disagreements or reportable events that required disclosure during this transition period. A formal letter from Moss Adams confirming their agreement with the company's statements has been filed with the U.S. Securities and Exchange Commission.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。